Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Interferon Alfa-2B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Pontificia Universidad Catolica de Chile
Deal Size : Not Applicable
Deal Type : Not Applicable
BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile
Details : The trial tests BetterLife’s proprietary inhaled interferon alpha-2b product, AP-003 administered via nebulizer. AP-003, being a Type I interferon, is a broad acting antiviral agent used in COVID-19 patients.
Brand Name : AP-003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 22, 2021
Lead Product(s) : Interferon Alfa-2B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Pontificia Universidad Catolica de Chile
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa-2B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : BetterLife Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The IFN-a2b treatment arms will receive BetterLife’s proprietary inhaled IFN-a2b product, AP-003, administered via nebulizer, twice daily for 10 days.
Brand Name : AP-003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 27, 2021
Lead Product(s) : Interferon Alfa-2B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : BetterLife Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Alfa-2B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Altum Pharmaceuticals has entered into a Letter of Intent with Pontificia Universidad Católica de Chile to conduct a randomized placebo-controlled trial (“IN2COVID”) in COVID-19 patients testing Altum’s proprietary inhaled interferon alpha-2b prod...
Brand Name : AP-003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 11, 2021
Lead Product(s) : Interferon Alfa-2B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon a2b
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : BetterLife Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Altum reports that in May 2020 management requested a pre-IND meeting with the FDA with the intent to discuss the planned development of AP-003 (Interferon Alpha-2b for inhalation) for the treatment of COVID-19.
Brand Name : AP-003
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 27, 2020
Lead Product(s) : Interferon a2b
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : BetterLife Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : AntiCovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : BetterLife Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum
Details : BetterLife has amended terms of the agreement entered into on May 6, 2020 with Altum to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AP-003, a potential COVID-19 treatment.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 11, 2020
Lead Product(s) : AntiCovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : BetterLife Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : AntiCovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : BetterLife Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum
Details : BetterLife has secured lock-up agreements from shareholders of Altum Pharmaceuticals Inc. representing 67.12% of the outstanding common shares of Altum. BetterLife and Altum entered collaboration to to commercialize and sell AP-003 for COVID-19.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : AntiCovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : BetterLife Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : AntiCovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : BetterLife Pharma
Deal Size : $20.0 million
Deal Type : Licensing Agreement
BetterLife Pharma Enters into a Licensing Agreement with Altum Pharmaceuticals
Details : BetterLife Pharma has been worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a COVID-19 treatment, from Altum Pharmaceuticals Inc.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $5.0 million
May 07, 2020
Lead Product(s) : AntiCovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : BetterLife Pharma
Deal Size : $20.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?